Nav: Home

Cancer studies should include overweight, elderly mice

May 31, 2016

ST. LOUIS -- Researchers should include laboratory mice that are old and obese in their studies of immunotherapy treatments for cancer, according to a review article by Saint Louis University scientists.

"Because most cancer patients are older than 60 years of age, it can be convincingly argued that all preclinical studies testing novel immunotherapies or new combinations should include older mice. Yet this approach is rarely taken," says Ryan Teague, Ph.D., associate professor of molecular microbiology and immunology at Saint Louis University and the corresponding author of the article.

The article was the Feature Review of the June 2016 issue of "Trends in Immunology."

The potential of immunotherapy, using the body's immune system to fight disease, to save the lives of cancer patients is undeniable, Teague says. Yet, he adds, scientists are not using the best animal models to predict the effectiveness of immunotherapy in different populations.

Young, healthy mice are nearly universally used in cancer immunotherapy studies even though the immune system grows less responsive with aging. For example, T-cells, which identify pathogens and destroy them, aren't as plentiful and can't mount as robust of an attack as those in a younger person.

"Despite decades of research into the gradual deterioration of the immunity system during aging, this still represents fertile territory for clinically significant discoveries. Direct comparisons of old and young mice in translational preclinical investigation is crucial moving forward," Teague says.

"Older mice represent imperfect but valuable models for human immune aging, and may prove far more accurate than young mice in predicting the efficacy and potential toxicity of novel cancer immunotherapies in this major patient demographic."

His paper encourages researchers to use animal models that are young and old, lean and obese, and different in microbiota to better reflect the patient groups that develop cancer.

Research mice are considered elderly if they are between 16 and 24 months of age, Teague says.

Obesity and differing gut microbes can similarly impact using the body's own immune system as a weapon against cancer, Teague says.

"What determines the success of immunotherapy among diverse patient populations? Insight has come from recent mouse studies revealing that age, obesity and microbiota profoundly influence both natural immunity to cancer and the ability to effectively respond to immunotherapy. This area of investigation is in its infancy, but results are sufficiently compelling to force new thinking into how human cancer immunotherapy is modeled in mice."
Lauryn E. Klevorn and Ryan M. Teague are authors of the paper, "Adapting Cancer Immunotherapy Models for the Real World." The research was supported by a grant from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID; RO1A1087764), a Cancer Research Institute "Clinic and Laboratory Integration Program (CLIP) award and a grant from the Siteman Cancer Center and The Foundation for Barnes-Jewish Hospital to Teague. Klevorn was supported by a Saint Louis University Presidential Graduate Fellowship.

Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first medical degree west of the Mississippi River. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: infectious disease, liver disease, cancer, heart/lung disease, and aging and brain disorders.

Saint Louis University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...